Merged from 2 sources — review for redundancy.
Suppressor of Cytokine Signaling 3 (SOCS3) is an intracellular negative feedback regulator that acts as a molecular brake on the JAK-STAT pathway, specifically targeting Leptin and Insulin receptor signaling. It functions as a checkpoint molecule that prevents runaway inflammatory and metabolic signaling, but when chronically elevated in states of chronic low-grade inflammation, it creates a paradoxical state of hormone resistance despite high circulating hormone levels. SOCS3 is the primary molecular mechanism linking metaflammation to Leptin resistance and metabolic dysfunction.
Imagine a thermostat with a broken sensor. Your house is freezing, so the heating system cranks up to maximum, pumping out hot air constantly. But the thermostat itself is covered in dust and grime (representing chronic inflammation), so it can't properly detect the heat that's being produced. It keeps reading "cold" even though the radiators are blazing. So it signals the boiler to work even harder, creating more and more heat that it still can't sense. The dust on the sensor is SOCS3—it's blocking the signal that should tell the system "we have enough heat, stop making more."
In your body, fat cells are pumping out massive amounts of Leptin (the "heat") to signal the brain "we have enough energy stored, stop eating, burn more calories." But chronic inflammation from processed foods, sedentary behavior, and stress has turned on SOCS3 in the hypothalamus (the "dust on the thermostat"). This blocks the leptin signal from getting through. So the brain keeps reading "starvation mode" even though fat stores are overflowing. It tells you to eat more, conserve energy, and the vicious cycle deepens. The system isn't broken because of too little leptin—it's broken because the signaling pathway has been muffled by its own regulatory mechanism stuck in the "on" position.
SOCS3 operates through a classic negative feedback loop that becomes pathological when chronically activated:
1. Activation cascade:
- Leptin binds to leptin receptor (LepRb) on hypothalamic neurons
- This activates JAK2 (Janus kinase 2) tyrosine kinase at the receptor
- JAK2 phosphorylates STAT3 (Signal Transducer and Activator of Transcription 3)
- Phosphorylated STAT3 dimerizes and translocates to the nucleus
- Nuclear STAT3 binds to SOCS3 gene promoter → induces SOCS3 transcription
- SOCS3 protein is synthesized and exported to cytoplasm
2. Inhibitory mechanism:
- SOCS3 contains an SH2 domain (Src Homology 2) that binds phosphotyrosine residues
- It binds directly to phosphorylated Tyr985 on the leptin receptor
- It also binds to the activation loop of JAK2 kinase
- SOCS3 contains a SOCS box domain that recruits E3 ubiquitin ligase complex
- This tags the receptor-JAK2 complex for proteasomal degradation
- Net effect: blocks further STAT3 phosphorylation and downstream signaling
3. Cross-pathway interference:
4. Inflammatory amplification:
- IL-6, TNF-α, and other inflammatory cytokines also activate JAK-STAT
- These cytokines induce SOCS3 via the same STAT3 pathway
- In chronic inflammation, continuous cytokine exposure = continuous SOCS3 expression
- This creates a state of "selective resistance" where metabolic signals are blocked but inflammatory signals persist
graph TD
A[Leptin binds LepRb] --> B[JAK2 activation]
B --> C[STAT3 phosphorylation]
C --> D[pSTAT3 nuclear translocation]
D --> E[SOCS3 gene transcription]
E --> F[SOCS3 protein synthesis]
F --> G{SOCS3 inhibitory actions}
G --> H[Binds JAK2 activation loop]
G --> I[Binds LepRb Tyr985]
G --> J[Recruits E3 ubiquitin ligase]
H --> K[Blocks STAT3 phosphorylation]
I --> K
J --> L[Receptor degradation]
M["IL-6/TNF-α"] --> C
N[Insulin receptor] --> O[IRS-1/2]
F --> P[Binds insulin receptor]
P --> Q[Blocks IRS phosphorylation]
Q --> R[Insulin resistance]
K --> S[Leptin resistance]
style F fill:#ff9999
style S fill:#ffcccc
style R fill:#ffcccc
Clinical thresholds:
- SOCS3 mRNA expression increases 3-5 fold in obese adipose tissue
- SOCS3 protein expression correlates with BMI >30 kg/m²
- Hypothalamic SOCS3 elevation detectable with IL-6 >10 pg/mL
- Effects measurable within 2-4 hours of acute inflammatory stimulus
SOCS3 is the molecular lynchpin connecting chronic low-grade inflammation to metabolic disease, making it central to cPNI practice:
Primary clinical relevance:
-
Obesity and weight loss resistance: Patients with elevated inflammatory markers (hsCRP >3 mg/L, IL-6 >5 pg/mL) often show Leptin resistance mediated by SOCS3. This explains why high leptin levels (>15 ng/mL in men, >25 ng/mL in women) paradoxically predict weight gain and metabolic dysfunction. The brain cannot "hear" the leptin signal, so appetite suppression and metabolic rate increases don't occur.
-
Type 2 Diabetes and Insulin resistance: SOCS3 simultaneously blocks both leptin and insulin signaling, creating the dual hormone resistance characteristic of metabolic syndrome. This is why treating inflammation (rather than just lowering glucose) can restore insulin sensitivity—you're addressing the SOCS3 brake rather than just pushing harder on the metabolic accelerator.
-
Metaflammation syndrome: SOCS3 is the mechanistic bridge in the "inflammation → obesity → more inflammation" vicious cycle. Adipose tissue inflammation → IL-6/TNF-α → hypothalamic SOCS3 → leptin resistance → increased adiposity → more adipose inflammation. Breaking this cycle requires addressing the inflammatory drivers.
Evolutionary mismatch perspective:
SOCS3 is an ancient protective mechanism—it evolved to prevent excessive energy expenditure during acute infection (when you need to conserve resources for immune function). The selfish immune system temporarily overrides metabolic hormones to prioritize survival. But this system was designed for transient infections, not for chronic exposure to processed foods, sedentary behavior, and psychosocial stress that create permanent inflammatory signaling.
Intervention implications:
-
Anti-inflammatory nutrition: Reduce triggers of SOCS3 expression by addressing gut dysbiosis, leaky gut, and dietary AGEs. Omega-3 fatty acids (EPA >2g/day) specifically reduce SOCS3 expression.
-
Intermittent fasting/time-restricted eating: Reduces baseline inflammation and allows SOCS3 levels to normalize during fasting windows. The 5 plus 2 metamodel leverages this mechanism.
-
Exercise: Acute exercise transiently increases IL-6 (myokine release), but chronic training reduces systemic inflammation and SOCS3 expression. This is "hormesis" at the molecular level.
-
Address root inflammatory sources: Periodontal disease (Porphyromonas gingivalis), chronic infections, obesity-related adipose inflammation—all drive continuous SOCS3 expression. Clinical success requires treating these upstream drivers, not just prescribing leptin or insulin.
Metamodel connections:
- Metamodel 1 (inflammation): SOCS3 is the mechanistic output of chronic inflammatory signaling
- Metamodel 3 (metabolism): SOCS3 creates metabolic inflexibility by blocking hormone signaling
- Metamodel 5 (movement neglect): Sedentary behavior increases inflammation → SOCS3 → metabolic dysfunction
- SOCS3 expression peaks 2-4 hours after cytokine exposure, creating a delayed negative feedback
- Half-life of SOCS3 protein is approximately 2 hours under normal conditions, but prolonged in chronic inflammation
- SOCS3 is induced by all cytokines that signal through JAK-STAT (IL-6, IL-10, IL-11, IFN-γ, leptin itself)
- Hypothalamic SOCS3 elevation occurs before peripheral insulin resistance develops—it's an early warning sign
- SOCS3 knockout mice are resistant to diet-induced obesity and maintain leptin sensitivity
- Adipose tissue SOCS3 expression is 3-10 fold higher in obesity compared to lean controls
- SOCS3 blocks leptin signaling in arcuate nucleus neurons, specifically affecting POMC (pro-opiomelanocortin) and AgRP neurons
- In pregnancy, placental SOCS3 helps create physiological insulin resistance—a normal adaptation gone pathological in gestational diabetes
- SOCS3 also regulates testosterone production: Leptin → SOCS3 in Leydig cells → reduced JAK-STAT signaling → decreased testosterone synthesis (explains hypogonadism in obesity)
- Clinical biomarker pattern: High leptin + high IL-6 + normal/low adiponectin = likely SOCS3-mediated leptin resistance
- Resveratrol, Curcumin, and Omega-3 fatty acids specifically inhibit SOCS3 expression in preclinical models
- SOCS3 expression shows circadian variation, lowest in early morning (04:00-06:00), highest in evening—relevant for time-restricted eating protocols
- SOCS1 — closely related family member; SOCS1 preferentially inhibits IFN signaling while SOCS3 targets IL-6/leptin pathways
- JAK-STAT pathway — SOCS3 is the primary negative regulator of this pathway, creating a self-limiting feedback loop
- Leptin — SOCS3 is the main cause of hypothalamic leptin resistance in obesity and chronic inflammation
- Leptin resistance — SOCS3 elevation is THE molecular mechanism explaining why high leptin fails to suppress appetite
- Insulin resistance — SOCS3 blocks IRS-1/2 signaling, creating simultaneous insulin and leptin resistance
- Metaflammation — chronic low-grade inflammation drives continuous SOCS3 expression, linking inflammation to metabolic disease
- IL-6 — potent inducer of SOCS3 via STAT3 activation; both inflammatory (classical) and metabolic (trans-signaling) IL-6 pathways converge on SOCS3
- TNF-α — synergizes with IL-6 to amplify SOCS3 expression and worsen hormone resistance
- Chronic low-grade inflammation — the root cause of pathological SOCS3 elevation in modern metabolic disease
- Obesity — creates adipose inflammation → IL-6/TNF-α → SOCS3 → leptin resistance → more obesity (vicious cycle)
- Type 2 Diabetes — SOCS3-mediated insulin resistance in liver and muscle contributes to hyperglycemia
- Selfish immune system — SOCS3 is a mechanism by which immune system prioritizes its needs over metabolic homeostasis during threat
- AKT pathway — SOCS3 blocks insulin-induced AKT activation by preventing IRS phosphorylation
- STAT3 — both the activator of SOCS3 transcription and the target of SOCS3 inhibition (negative feedback)
- Hypothalamic Inflammation — neuroinflammation drives local SOCS3 expression, disrupting energy homeostasis control
- Arcuate nucleus — key site of SOCS3 action in leptin resistance; SOCS3 blocks leptin signaling in POMC and AgRP neurons
- Adiponectin — low adiponectin and high leptin with elevated SOCS3 is the signature of metabolic inflammation
- Trained immunity — metabolic reprogramming in trained immunity involves SOCS regulation of cytokine sensitivity
- Omega-3 fatty acids — EPA and DHA suppress SOCS3 expression via PPAR signaling and reduced NF-κB activation
- Intermittent fasting — reduces inflammatory tone and allows SOCS3 levels to normalize during fasting windows
- Exercise — chronic exercise training reduces systemic SOCS3 expression despite acute IL-6 elevation during workout
- Gut dysbiosis — LPS from gram-negative bacteria drives IL-6 → SOCS3 via TLR4 activation
- Testosterone — SOCS3 in Leydig cells blocks leptin-induced testosterone synthesis; explains hypogonadism in obesity
- Gestational diabetes — placental SOCS3 creates physiological insulin resistance; excessive SOCS3 contributes to pathology
- PCOS — SOCS3-mediated leptin and insulin resistance contributes to ovulatory dysfunction and metabolic features
- Module 1: Introduced as checkpoint regulator in metaflammation and immunometabolism context
- Module 7: Role in leptin resistance and metabolic dysfunction
- Module 8: SOCS3 mechanism in testosterone regulation and male hypogonadism
SOCS3 (Suppressor of Cytokine Signaling 3) is a negative feedback regulator of the JAK/STAT pathway that specifically blocks Leptin and Insulin receptor signaling by binding to JAK2 kinase and marking receptors for degradation. It represents the primary molecular mechanism linking chronic inflammation to metabolic dysfunction, converting adaptive acute stress responses into pathological leptin resistance and insulin resistance during chronic low-grade inflammation.
Think of SOCS3 as a thermostat override that gets stuck in the "off" position. Your furnace (leptin and insulin signaling) works perfectly, the fuel gauge (leptin levels) shows "full," and the control panel (insulin levels) is maxed out—but the house stays cold because someone taped over the thermostat sensor.
Here's how it happens: During an infection (acute inflammation), your body deliberately blocks leptin and insulin signaling for 1-2 hours—this is like temporarily turning down the heat to redirect energy to immune cells fighting the infection. SOCS3 is the circuit breaker that does this. Once the infection clears, SOCS3 levels drop, and normal signaling resumes.
But in chronic inflammation (obesity, gut dysbiosis, chronic stress), it's like the circuit breaker never resets. SOCS3 stays elevated 24/7. Now your hypothalamus can't "see" leptin telling it you're full, so you stay hungry despite high body fat. Your liver can't "hear" insulin telling it to stop making glucose, so blood sugar stays high despite high insulin. The signals are screaming, but SOCS3 has unplugged the receivers. This is why giving more leptin or more insulin doesn't work—the problem isn't the signal strength, it's the blocked receiver.
SOCS3 operates through a precisely timed negative feedback loop with pathological consequences during chronic activation:
Acute Induction Phase:
- Pro-inflammatory cytokines (IL-6, TNF-α) or metabolic hormones (Leptin, Insulin) bind their receptors
- Receptor-associated JAK2 kinase phosphorylates itself and the receptor
- Phosphorylated receptor recruits STAT3, which gets phosphorylated by JAK2
- p-STAT3 dimerizes and translocates to nucleus
- STAT3 binds to SOCS3 gene promoter → rapid SOCS3 mRNA transcription (peak at 1-2 hours)
- SOCS3 protein is synthesized and binds to JAK2 via its SH2 domain
Inhibition Mechanism:
7. SOCS3 binding to JAK2 blocks its catalytic activity (prevents further STAT3 phosphorylation)
8. SOCS3's SOCS box domain recruits Elongin B/C → Cullin 5 → Rbx2 (E3 ubiquitin ligase complex)
9. E3 complex ubiquitinates the receptor → proteasomal degradation
10. Result: Both functional inhibition (blocked JAK2) and receptor downregulation
Tissue-Specific Pathology:
Hypothalamic SOCS3 (Nucleus Arcuatus):
- Leptin receptor (ObRb) → JAK2 → STAT3 → SOCS3 (as above)
- SOCS3 blocks leptin activation of POMC neurons (satiety signals)
- SOCS3 blocks leptin inhibition of AgRP neurons (hunger signals)
- Result: Hyperphagia despite elevated leptin (>20 ng/mL typical in obesity)
- SOCS3 also blocks leptin's permissive effects on sympathetic outflow
Hepatic SOCS3:
- Insulin receptor (InsR) → IRS-1/2 phosphorylation → AKT pathway
- SOCS3 binds to InsR and IRS proteins, blocking IRS tyrosine phosphorylation
- Prevents AKT activation → gluconeogenesis genes (PEPCK, G6Pase) remain active
- Result: Hepatic glucose production continues despite hyperinsulinemia
- Also impairs insulin-mediated SREBP-1c activation → reduced lipogenesis but increased inflammation
Skeletal Muscle/Adipose SOCS3:
- Blocks insulin-stimulated GLUT4 translocation to cell membrane
- Impairs glucose uptake despite elevated insulin (>15 μU/mL fasting)
- Shifts metabolism toward GLUT1-mediated basal uptake (insulin-independent)
Immune Cell SOCS3:
- Blocks protective anti-inflammatory effects of leptin on T cells
- In obesity, prevents leptin from suppressing Th1/Th2 imbalance
- Creates selective leptin resistance (pro-inflammatory signals remain, anti-inflammatory blocked)
graph TD
A["IL-6/TNF-α/Leptin/Insulin"] --> B[Receptor Activation]
B --> C[JAK2 Phosphorylation]
C --> D[STAT3 Phosphorylation]
D --> E[STAT3 Nuclear Translocation]
E --> F[SOCS3 Gene Transcription]
F --> G[SOCS3 Protein]
G --> H[Binds JAK2 SH2 Domain]
H --> I[Blocks JAK2 Catalytic Activity]
G --> J["SOCS Box → E3 Ubiquitin Ligase"]
J --> K[Receptor Ubiquitination]
K --> L[Proteasomal Degradation]
I --> M{Tissue Context}
L --> M
M --> N["Hypothalamus: Leptin Resistance"]
M --> O["Liver: Insulin Resistance"]
M --> P["Muscle: Glucose Uptake Block"]
M --> Q["Immune: Anti-inflammatory Block"]
N --> R["Hyperphagia + Obesity"]
O --> S["Hyperglycemia + NAFLD"]
P --> S
Q --> T[Sustained Inflammation]
T -.feedback loop.-> A
R -.adipose inflammation.-> A
S -.metaflammation.-> A
style A fill:#ff9999
style G fill:#ffcc99
style R fill:#ff6666
style S fill:#ff6666
style T fill:#ff6666
SOCS3 is the molecular explanation for why obesity and chronic inflammation create a self-perpetuating metabolic trap—a central concept in the metaflammation model and the Selfish Brain theory.
Diagnostic Implications:
- Patients with elevated leptin (>15 ng/mL women, >8 ng/mL men) but continued hunger have functional leptin resistance mediated by SOCS3
- High insulin (>15 μU/mL fasting) with high glucose (>100 mg/dL) indicates SOCS3-mediated insulin resistance at the receptor level
- The leptin:adiponectin ratio (>1.5) correlates with hypothalamic SOCS3 expression
- HbA1c elevation despite hyperinsulinemia reflects hepatic SOCS3 blocking insulin's suppression of gluconeogenesis
Metamodel Connections:
This directly manifests Metamodel 1 (chronic low-grade inflammation as root pathology) and Metamodel 3 (the selfish systems competing for resources). SOCS3 represents the immune system's "selfish" override of metabolic hormones—adaptive in acute infection (redirecting glucose to leukocytes via GLUT1), pathological in chronic inflammation (creating metabolic disease).
Evolutionary Mismatch:
SOCS3 induction during acute infection is an evolutionarily conserved response to ensure leukocytes get glucose priority during pathogen challenge. The mechanism evolved for transient (hours-to-days) activation. Chronic activation from obesity, gut dysbiosis, chronic stress, and Western diet represents a profound mismatch disease—the circuit breaker that should reset in 24 hours stays tripped for years.
Clinical Intervention Strategy:
Breaking the SOCS3 cycle requires reducing the upstream inflammatory signals:
-
Gut barrier restoration → reduces LPS-driven TLR4 → NF-κB → IL-6 → SOCS3
-
Adipose tissue inflammation reduction → less macrophage infiltration → less TNF-α/IL-6
- Target: Weight loss (even 5-7% reduces adipose inflammation), omega-3 fatty acids (shift to SPM production), physical activity (muscle-derived IL-6 has different signaling profile)
-
Hypothalamic inflammation reversal → restore leptin sensitivity
- Target: Fasting protocols (12-16h overnight reduces hypothalamic inflammatory markers), DHA (crosses BBB, reduces microglial activation), eliminate fructose (directly induces hypothalamic ER stress)
-
Hepatic SOCS3 reduction → restore insulin sensitivity
Critical Clinical Point:
Measuring leptin or insulin levels alone is insufficient—you must assess functional sensitivity. A patient with leptin 30 ng/mL who is constantly hungry has SOCS3-mediated resistance. Simply adding exogenous leptin fails (the receptor is blocked). The inflammation must be addressed first. This is why type 2 diabetes patients often have sky-high insulin yet worsening hyperglycemia—SOCS3 has functionally uncoupled the insulin signal from its metabolic effects.
Exam-Relevant Clinical Vignette:
Patient presents with BMI 34, fasting glucose 118 mg/dL, fasting insulin 22 μU/mL, leptin 28 ng/mL, CRP 4.8 mg/L, reports constant hunger despite high caloric intake. This is SOCS3-mediated dual resistance. Treatment: Address inflammation first (anti-inflammatory diet, gut health, movement), not more insulin or appetite suppressants.
- SOCS3 mRNA expression peaks 1-2 hours after cytokine exposure, protein persists 4-8 hours in acute inflammation
- In obesity, hypothalamic SOCS3 expression is elevated 5-10 fold compared to lean individuals
- SOCS3 knockout specifically in POMC neurons restores leptin sensitivity and reduces food intake by 40% in obese mice
- Hepatic SOCS3 overexpression increases fasting glucose by 30-40 mg/dL despite normal insulin levels
- SOCS3 expression correlates directly with HbA1c (r=0.61) and HOMA-IR (r=0.58) in clinical studies
- IL-6 is the most potent SOCS3 inducer (10x more than TNF-α on molar basis)
- SOCS3 binds to insulin receptor at Tyr960 residue, the same site required for IRS-1 binding—direct competition
- Adipose tissue SOCS3 expression increases 3-4 fold for every 5-point BMI increase above 25
- SOCS3 half-life is ~2 hours, requiring continuous inflammatory signaling to maintain elevated levels
- Leptin paradoxically induces its own resistance via SOCS3—creating positive feedback loop in obesity
- SOCS3 polymorphisms (rs4969170) associated with increased risk of metabolic syndrome in multiple populations
- DHA supplementation (2g/day) reduces hypothalamic SOCS3 expression by ~35% in animal models
- Time-restricted feeding (≤8h eating window) reduces hepatic SOCS3 expression independent of weight loss
- SOCS1 — SOCS1 and SOCS3 work synergistically as cytokine checkpoint regulators; SOCS1 primarily targets IFN-γ/IL-2 signaling while SOCS3 targets IL-6/leptin/insulin
- SOCS — SOCS3 is the most clinically significant family member in metabolic disease pathogenesis
- JAK/STAT pathway — SOCS3 is the primary negative feedback regulator of JAK2-STAT3 signaling in metabolic tissues
- leptin resistance — SOCS3 is the dominant molecular mechanism causing leptin resistance in obesity; explains why high leptin doesn't suppress appetite
- insulin resistance — SOCS3 blocks insulin receptor substrate phosphorylation, creating receptor-level insulin resistance distinct from post-receptor defects
- metaflammation — SOCS3 is the molecular link between chronic inflammation and metabolic dysfunction defining metaflammation
- IL-6 — Most potent inducer of SOCS3 via STAT3 activation; explains IL-6's dual role in acute adaptation vs chronic pathology
- TNF-α — Induces SOCS3 expression via NF-κB and contributes to insulin resistance in obesity
- Leptin — Creates self-perpetuating resistance loop: leptin → SOCS3 → leptin resistance → compensatory hyperleptinemia → more SOCS3
- Insulin — SOCS3 blocks insulin signaling at receptor level, explaining hyperinsulinemic insulin resistance
- obesity — Obesity-related adipose inflammation sustains elevated SOCS3 in hypothalamus, liver, and muscle
- hypothalamus — Site of SOCS3-mediated leptin resistance causing hyperphagia and reduced energy expenditure
- Nucleus Arcuatus — Specific hypothalamic nucleus where SOCS3 blocks leptin action on POMC and AgRP neurons
- GLUT1 — SOCS3-mediated insulin resistance shifts glucose uptake from insulin-dependent GLUT4 to constitutive GLUT1, benefiting immune cells
- GLUT4 — Insulin-stimulated GLUT4 translocation is blocked by SOCS3, impairing muscle and adipose glucose uptake
- type 2 diabetes — SOCS3-mediated hepatic insulin resistance is key mechanism in progression from prediabetes to T2D
- metabolic syndrome — SOCS3 elevation links all five components: inflammation drives SOCS3, which creates insulin resistance, hypertension, dyslipidemia
- chronic low-grade inflammation — Maintains pathologically elevated SOCS3 levels, converting adaptive acute responses into chronic disease
- NF-κB — NF-κB activation by inflammatory signals induces SOCS3 gene transcription independent of STAT3 pathway
- Chronic Kidney Disease — SOCS3 elevation in CKD contributes to uremic insulin resistance and inflammation
- NAFLD — Hepatic SOCS3 elevation drives insulin resistance and blocks insulin's lipogenic effects, worsening steatosis
- HbA1c — SOCS3 expression correlates with HbA1c levels; hepatic SOCS3 prevents insulin from suppressing gluconeogenesis
- CRP — Elevated CRP (>3 mg/L) correlates with increased SOCS3 expression and predicts leptin/insulin resistance development
- adiponectin — Adiponectin suppresses SOCS3 expression; low adiponectin:leptin ratio predicts SOCS3-mediated resistance
- omega-3 fatty acids — EPA/DHA reduce SOCS3 expression by shifting from pro-inflammatory eicosanoids to Specialized pro-resolving mediators (SPMs)
- Berberine — Reduces hepatic SOCS3 expression via AMPK activation, improving insulin sensitivity
- curcumin — Inhibits STAT3 phosphorylation, reducing SOCS3 transcription and breaking inflammation-resistance cycle
- intermittent fasting — Reduces hepatic and hypothalamic SOCS3 expression independent of weight loss via metabolic reprogramming
- gut dysbiosis — Dysbiosis-driven LPS elevation activates TLR4 → NF-κB → IL-6 → SOCS3 pathway
- LPS — Lipopolysaccharide from gram-negative bacteria is potent SOCS3 inducer via TLR4 signaling
- TLR4 — Toll-like receptor 4 activation by LPS or saturated fats induces SOCS3 via both NF-κB and STAT3 pathways